-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RfmIQ0qCixYpg6dGyZ++KaQwdHQOSkHehslwezvjIBhHFvQj2TlqiWiFGclnIcra BB90Gb14KURH8UQ9KmA6Gw== 0001144204-03-007762.txt : 20031121 0001144204-03-007762.hdr.sgml : 20031121 20031120182237 ACCESSION NUMBER: 0001144204-03-007762 CONFORMED SUBMISSION TYPE: 10QSB/A PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20030930 FILED AS OF DATE: 20031121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MOLECULAR DIAGNOSTICS INC CENTRAL INDEX KEY: 0000075439 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 364296006 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10QSB/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-00935 FILM NUMBER: 031016389 BUSINESS ADDRESS: STREET 1: 900 NORTH FRANKLIN STREET STREET 2: SUITE 210 CITY: CHICAGO STATE: IL ZIP: 60610 BUSINESS PHONE: 4078490290 MAIL ADDRESS: STREET 1: 900 NORTH FRANKLIN STREET 1 STREET 2: SUITE 210 CITY: CHICAGO STATE: IL ZIP: 60610 FORMER COMPANY: FORMER CONFORMED NAME: AMPERSAND MEDICAL CORP DATE OF NAME CHANGE: 19990527 FORMER COMPANY: FORMER CONFORMED NAME: BELL NATIONAL CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC COAST HOLDINGS INC DATE OF NAME CHANGE: 19830303 10QSB/A 1 molecular.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-QSB/A (Mark One) |X| QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2003 |_| TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ___________ to ___________. Commission File number 0-935 MOLECULAR DIAGNOSTICS, INC. (Exact name of Small Business Issuer as Specified in Its Charter) Ampersand Medical Corporation (Former Name of Small Business Issuer) Delaware 36-4296006 - ------------------------------- ------------------ (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 414 North Orleans Street, Suite 510 Chicago, IL 60610 ---------------------------------------- (Address of Principal Executive Offices) (312) 222-9550 --------------------------- (Issuer's Telephone Number) N/A ---------------------------------------------------- (Former name, former address and former fiscal year, if changed since last report) Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes |X| No |_| APPLICABLE ONLY TO CORPORATE ISSUERS State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date. Common Stock, $0.001 par value 39,640,532 - ------------------------------ ----------------------------------------- (Class) Outstanding shares as of October 31, 2003 Transitional Small Business Disclosure Format (Check One): Yes |_| No |X| MOLECULAR DIAGNOSTICS, INC. QUARTERLY REPORT ON FORM 10-QSB September 30, 2003 TABLE OF CONTENTS Page ---- PART I. -- FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) a) Consolidated Balance Sheets - September 30, 2003 and December 31, 2002 .................................................. 3 b) Consolidated Statements of Operations -- Three months and nine months ended September 30, 2003 and 2002 ...................... 4 c) Consolidated Statements of Cash Flows -- Nine months ended September 30, 2003 and 2002 ........................................ 5 d) Notes to Consolidated Financial Statements - September 30, 2003 ...... 6 Item 2. Management's Discussion and Analysis or Plan of Operation ......... 17 Item 3. Controls and Procedures ........................................... 22 PART II.-- OTHER INFORMATION Item 1. Legal Proceedings ................................................. 23 Item 2. Changes In Securities and Use of Proceeds ......................... 25 Item 3. Defaults Upon Senior Securities ................................... 26 Item 4. Submission of Matters to a Vote of Security Holders ............... 26 Item 5. Other Information ................................................. 26 Item 6. Exhibits and Reports on Form 8-K .................................. 26 SIGNATURES ................................................................ 27 EXHIBIT INDEX ............................................................. 28 2 Part I. -- Financial Information Item 1. Financial Statements MOLECULAR DIAGNOSTICS, INC. AND SUBSIDIARIES (Formerly Ampersand Medical Corporation) CONSOLIDATED BALANCE SHEETS (Dollars in thousands)
September 30, December 31, 2003 2002 ------------- ------------ (Unaudited) Assets Current Assets: Cash and cash equivalents .......................................................... $ 124 $ 42 Accounts receivables, net of allowance for doubtful accounts of $ 65 and $ 145 at September 30, 2003 and December 31, 2002, respectively .......................... 335 307 Inventories ........................................................................ 181 427 Refundable taxes ................................................................... 50 56 Prepaid financings costs ........................................................... 326 288 Prepaid expenses and other current assets .......................................... 35 69 -------- -------- Total current assets .................................................... 1,051 1,189 Fixed Assets, net ..................................................................... 477 666 Other Assets Licenses, patents, and technology, net of amortization ............................. 7,038 7,521 Goodwill, net of amortization ...................................................... 283 283 -------- -------- Total assets ............................................................ $ 8,849 $ 9,659 ======== ======== Liabilities and Stockholders' Equity (Deficit) Current Liabilities: Accounts payable ................................................................... $ 5,241 $ 5,202 Customer and other deposits ........................................................ 24 Accrued payroll costs .............................................................. 2,027 1,856 Accrued expenses ................................................................... 1,433 1,143 Deferred revenue ................................................................... 542 630 Revolving line of credit ........................................................... 280 207 Due to stockholder ................................................................. 140 127 Lease obligation ................................................................... 279 279 Notes payable--related party ....................................................... 596 65 Notes payable ...................................................................... 6,358 4,585 -------- -------- Total current liabilities ............................................... 16,896 14,118 Deferred revenue, less current portion ................................................ 75 120 -------- -------- Total liabilities ....................................................... 16,971 14,238 -------- -------- Stockholders' Equity (Deficit): Preferred stock, $0.001 par value; shares authorized - 10,000,000; shares issued and outstanding - 2,511,621 and 2,781,024, at September 30, 2003 and December 31, 2002, respectively ........................................................................ 12,905 16,958 Common stock, $0.001 par value; shares authorized - 100,000,000; shares issued and outstanding - 39,196,699 and 36,440,700, at September 30, 2003 and December 31, 2002, respectively ........................................................................ 39 37 Additional paid-in-capital ............................................................ 28,705 19,557 Treasury stock; 192,088 shares at September 30, 2003 and December 31, 2002 ............ (327) (327) Deferred compensation ................................................................. -- (11) Accumulated deficit ................................................................... (49,207) (40,642) Accumulated comprehensive loss-- Cumulative translation adjustment ............................................ (237) (151) -------- -------- Total stockholders' equity (deficit) .................................... (8,122) (4,579) -------- -------- Total liabilities and stockholders' equity (deficit) .................... $ 8,849 $ 9,659 ======== ========
The accompanying notes are an integral part of these consolidated financial statements. 3 MOLECULAR DIAGNOSTICS, INC. (Formerly Ampersand Medical Corporation) CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in thousands, except per share amounts)
For the nine Months For the three Months Ended September 30, Ended September 30, ------------------------- ------------------------- 2003 2002 2003 2002 ---------- ---------- ---------- ---------- (Unaudited) (Unaudited) Net revenues ...................................... $ 1,280 $ 1,453 $ 262 $ 295 Operating expenses Cost of revenues .............................. 667 644 159 162 Research and development ...................... 448 3,402 129 867 Selling, general, and administrative expenses . 5,699 6,162 2,489 1,740 ---------- ---------- ---------- ---------- Total operating expenses ................. 6,814 10,208 2,777 2,769 ---------- ---------- ---------- ---------- Operating loss .................................... (5,534) (8,755) (2,515) (2,474) Other income (expense): Interest (expense) -related party ............. (67) (16) (32) (7) Interest (expense) ............................ (2,568) (1,447) (1,311) (575) Gain on litigation settlement ................. -- 151 -- -- Other, net .................................... 47 -- 41 -- ---------- ---------- ---------- ---------- Total other income (expense) ............. (2,588) (1,312) (1,302) (582) ---------- ---------- ---------- ---------- Loss before income taxes .......................... (8,122) (10,067) (3,817) (3,056) Income tax expense ................................ -- -- -- -- ---------- ---------- ---------- ---------- Net loss .......................................... $ (8,122) $ (10,067) $ (3,817) $ (3,056) ========== ========== ========== ========== Preferred stock dividend .......................... (1,113) (996) (361) (582) ---------- ---------- ---------- ---------- Net loss applicable to common stockholders ........ $ (9,235) $ (11,063) $ (4,178) $ (3,638) ========== ========== ========== ========== Basic and fully diluted net loss per common share . $ (0.23) $ (0.43) $ (0.11) $ (0.14) ========== ========== ========== ========== Weighed average number of common shares outstanding 40,191,128 25,956,783 38,858,622 26,550,822 ========== ========== ========== ==========
The accompanying notes are an integral part of these consolidated financial statements. 4 MOLECULAR DIAGNOSTICS, INC. (Formerly Ampersand Medical Corporation) CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in thousands)
Nine Months Ended September 30, -------------------- 2003 2002 ------- -------- (Unaudited) Operating Activities: Net loss ....................................................................... $(8,122) $(10,067) Adjustments to reconcile net loss to net cash used for operating activities: Amortization of debt discount ............................................. 2,139 1,162 Depreciation and amortization ............................................. 683 725 Amortization of fees ...................................................... 350 -- Loss on sale of fixed assets .............................................. 1 -- Fixed assets exchanged for services ....................................... 8 -- Stock, warrants, and options issued to non-employees for services ......... 1,984 677 Licensing fees recognized on preferred stock sale ......................... -- (298) Compensation expense related to stock appreciation rights, stock options, and restricted stock ................................................. 12 87 Interest expense paid with stock .......................................... -- 116 Changes in assets and liabilities: Accounts receivable, net ............................................. 1 124 Inventories .......................................................... 262 4 Refundable taxes ..................................................... 11 78 Due from (to) stockholder ............................................ 13 69 Prepaid expenses and other current assets ............................ (468) (14) Accounts payable ..................................................... 122 2,539 Deposits ............................................................. (24) (28) Deferred revenue ..................................................... (153) 276 Accrued expenses ..................................................... 401 829 ------- -------- Net cash used for operating activities (2,780) (3,721) ------- -------- Cash used in investing activities: Expenditures for license, patents, and technology .............................. -- (4) Capital purchases .............................................................. (18) (88) ------- -------- Net cash used for investing activities ......................................... (18) (92) ------- -------- Cash flows from financing activities: Proceeds from issuance of convertible notes payable ............................ 1,843 2,549 Proceeds from issuance of senior debt note payable ............................. 650 Proceeds from issuance of convertible notes payable, related party ............. 1,015 25 Note issued in payment of an expense ........................................... 339 -- Payment of notes payable ....................................................... (373) (290) Proceeds (Payment) of revolving line of credit, net ............................ 49 (64) Proceeds from sale of fixed assets ............................................. -- -- ------- -------- Net cash provided by financing activities .......................................... 2,873 2,870 ------- -------- Effect of exchange rate changes on cash and cash equivalents ....................... 7 (80) ------- -------- Net increase (decrease) in cash and cash equivalents ............................... 82 (1,023) Cash and cash equivalents at the beginning of period ............................... 42 1,025 ------- -------- Cash and cash equivalents at end of period ......................................... $ 124 $ 2 ======= ======== Supplemental disclosure of cash flow information: Cash paid during the period for: Interest .................................................................. $ 18 $ 19 Non-cash transactions during the period for: Deferred financing costs .................................................. $ 1,652 $ -- Preferred stock and cumulative dividends converted into common stock ...... $ 4,495 $ 613
The accompanying notes are an integral part of these consolidated financial statements. 5 MOLECULAR DIAGNOSTICS, INC. (Formerly Ampersand Medical Corporation) NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited - September 30, 2003) Note 1. Organization Molecular Diagnostics, Inc, ("MDI") was incorporated as Ampersand Medical Corporation in Delaware on December 15, 1998, as the successor to Bell National Corporation ("Bell National"). Bell National was incorporated in California in 1958. On September 25, 2001, the Company changed its corporate name to Molecular Diagnostics, Inc. in order to better represent its operations and products. The name change was effected through a merger with a wholly-owned subsidiary. Molecular Diagnostics, Inc. has retained its Certificate of Incorporation, except as amended to reflect the new name, bylaws and capitalization. On December 4, 1998, Bell National (then a shell corporation without any business activity) acquired InPath, LLC, a development-stage company engaged in the design and development of medical instruments and related tests. In the acquisition, Bell National issued 4,288,790 shares of common stock and warrants to purchase 3,175,850 shares of common stock to the members of InPath in exchange for their units of membership interest in InPath and the senior executives of InPath assumed management control of MDI. Based upon the terms of the acquisition agreement, for financial reporting and accounting purposes the acquisition was accounted for as a reverse acquisition whereby InPath is deemed to have acquired Bell National. However, Bell National was the continuing legal entity and registrant for both Securities and Exchange Commission filing purposes and income tax filing purposes, until its merger into MDI in May 1999. Because Bell National was a non-operating public shell company with nominal assets and InPath was a private operating company, the acquisition was recorded as the issuance of stock for the net monetary assets of Bell National, accompanied by a recapitalization and no goodwill or other intangible assets were recorded. On September 17, 2001, Molecular Diagnostics, Inc. completed an acquisition transaction whereby AccuMed International, Inc. was merged into a wholly-owned subsidiary of MDI. The value of the transaction was approximately $14,178,000. Accordingly, the consolidated financial statements presented hereunder include the operations of InPath from March 16, 1998 (inception), the operations of Bell National and Molecular Diagnostics, Inc. from December 4, 1998, and the operations of AccuMed International, Inc. from September 17, 2001, the date of acquisition. Molecular Diagnostics, Inc. has another wholly owned subsidiary, Samba Technologies, Sarl ("Samba"). MDI acquired all of the assets of Samba in January 1999 from Unilog Regions, SA for approximately $500,000. Samba designs, develops, and markets web-enabled software based systems for image analysis, image capture, and image transmission and management for clinical and industrial applications. Samba is also developing software used in the InPath System. A majority of reported revenues prior to 2002 and since inception of Molecular Diagnostics, Inc. have been generated by Samba. Since December 20, 2002, Samba has operated under the protection of the French Commercial Court in compliance with the bankruptcy laws of France. Samba continues to maintain normal operations under the supervision of an Administrator appointed by the French Commercial Court. Samba will continue to operate under the current format until the Commercial Court approves a plan of reorganization and continuation. The Court must act by December 2003 unless an extension of time is granted. MDI has retained French legal counsel, who is working with the court and Samba management to develop a plan to submit to the courts by the end of November 2003. Molecular Diagnostics, Inc. is focused on the design, development and marketing of the InPath System, Samba software and related image analysis systems, including the AcCell instrument platforms. The InPath System and related products are intended to detect cancer and cancer related diseases. These products may be used in a laboratory, clinic, or doctor's office. Molecular Diagnostics, Inc. has incurred significant operating losses since its inception. Management expects that significant on-going operating expenditures will be necessary to successfully implement MDI's business plan and 6 develop, manufacture and market its products. These circumstances raise substantial doubt about MDI's ability to continue as a going concern. Implementation of its plans and its ability to continue as a going concern depend upon its securing substantial additional financing. During the first nine months of 2003, MDI raised a net cash investment of $1,858,200 in promissory notes and $1,000,000 in related party promissory notes. Management's continuing plans include substantial efforts to obtain additional capital. If Molecular Diagnostics, Inc. is unable to obtain adequate additional financing or generate profitable sales revenues, management may be required to curtail its product development and other activities and may be forced to cease operations. Note 2. Basis of Presentation The consolidated financial statements included herein were prepared by us without audit according to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been omitted pursuant to such rules and regulations. The consolidated financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the consolidated financial position and results of operations as of and for the periods indicated. The results of operations for the nine months and three months ended September 30, 2003, are not necessarily indicative of the results to be expected for the full year or for any other period. The consolidated financial statements include Molecular Diagnostics, Inc. and its wholly owned subsidiaries. All inter-company balances and transactions have been eliminated. These financial statements should be read in conjunction with the audited financial statements and the notes thereto included in our 2002 Annual Report on Form 10-K, as filed with the Securities and Exchange Commission. Note 3. Licenses, Patents, Technology, and Goodwill (in thousands) September 30, December 31, 2003 2002 ------- ------- Licenses .......................................... $1,029 $1,028 Patent costs ...................................... 133 133 MDI Technology Agreement .......................... 7,230 7,230 Dianon Technology Agreement ....................... 260 260 ------- ------- Subtotal .......................................... 8,652 8,651 Less accumulated amortization ..................... (1,614) (1,130) ------- ------- Total .................................... $ 7,038 $ 7,521 ======= ======= Goodwill .......................................... $ 283 $ 283 ======= ======= Aggregate Amortization Expense For the nine months ended September 30, 2003 .. $484 ==== Note 4. Accrued Expenses Accrued expenses include the following at September 30, 2003 and December 31, 2002 (in thousands): 2003 2002 ------ ------ Accrued interest ....................................... $ 587 $ 155 Accrued interest--related party ........................ 79 111 Accrued professional fees .............................. 2 146 Accrued taxes .......................................... 444 412 Reserve for warranty ................................... 18 21 Other accrued expenses ................................. 303 298 ------ ------ Total ......................................... $1,433 $1,143 ====== ====== MDI is delinquent in filing certain Federal and State Income Tax returns for 2002 and 2001. MDI is also delinquent in paying a portion of Federal and State employee and employer payroll taxes for 2003, 2002 and 2001. 7 The Company owed $736,000 and $678,000 as of September 30, 2003 and December 31, 2002, respectively, in past-due payroll taxes, including $241,000 and $250,000 respectively in assessed and estimated statutory penalties and interest. The Internal Revenue Service has filed a lien against the Company's assets to secure the unpaid payroll taxes. MDI is currently in the process of communicating through counsel with the Internal Revenue Service to resolve this matter. The amount is included in accrued payroll costs in the accompanying balance sheet. MDI is also delinquent in paying various state franchise taxes. Note 5. Notes Payable--Related Parties Notes payable to related parties at September 30, 2003 and December 31, 2002 (in thousands) consisted of:
2003 2002 ---- ---- Northlea Partners, Ltd., $25,000 Promissory Note issued August 6, 2001; interest rate 15% per annum ................................................... $ 25 $25 Northlea Partners, Ltd., $15,000 Promissory Note issued September 20, 2001; interest rate 9% per annum .................................................... 15 15 Northlea Partners, Ltd., $15,000 Bridge II convertible promissory note Issued May 1, 2003; interest rate 12% per annum; (see description under Bridge II notes in Note 6 - Notes payable, for other terms and conditions ..... 15 -- Robert Shaw, $25,000 Promissory Note issued September 20, 2001; interest rate 9% per annum .................................................................. 25 25 Suzanne M. Gombrich, $1,000,000 convertible promissory note issued April 2, 2003; maturity date April 2, 2004 or earlier; interest rate 12% per annum; convertible into common stock at $0.10 per share; beneficial conversion feature valued at $970,000; 1,000,000 warrants at exercise price of $0.15 per share; first priority security interest in all MDI assets .. 516 -- ---- --- $596 $65 ==== ===
On April 2, 2003, MDI issued a $1,000,000 Convertible Promissory Note to an affiliate, Suzanne M. Gombrich, the wife of Peter Gombrich, MDI's Chairman and CEO, in exchange for cash. The note bears interest at the rate of 12% per annum and is convertible into the common stock of MDI at a conversion price of $0.10 per share. As additional consideration, MDI granted the holder a warrant to purchase 1,000,000 shares of the common stock of MDI at an exercise price of $0.15 per share. MDI also granted the holder a first priority security interest in all of the Company's assets. The conversion price of the note was less than the market price of the common stock when the note was issued; therefore, the holder is considered to have a beneficial conversion feature. MDI determined the value of the beneficial conversion feature to be $970,000 using the fair value interest method. The value was recorded as a reduction of the debt and will be amortized as additional interest over the life of the note. MDI recorded additional interest expense of $486,000 to reflect amortization of the discount from the time the note was issued until September 30, 2003. The initial $100,000 of cash proceeds of the note was received in March 2003 and was used to fund the cost of an option to repurchase all of its assets from Round Valley Capital, LLC. The remaining proceeds received on April 2, 2003 were used to make the $900,000 payment required to exercise the purchase option in conjunction with the final settlement of the loan with Round Valley Capital, LLC. See Footnote 6 - Notes Payable, regarding events of default. The carrying amount of notes payable - related parties approximates fair value at September 30, 2003 and December 31, 2002. 8 Note 6. Notes Payable Notes payable to unrelated parties at September 30, 2003 and December 31, 2002 (in thousands) consisted of:
2003 2002 ------ ------ Bridge I Convertible Promissory Notes; due December 31, 2002; interest rate 7% per annum; convertible into common stock at 75% of the market price on date of conversion; beneficial conversion feature valued at $1,041,066; Bridge Warrants at an exercise price of $0.25 per share; Private Warrants at an exercise price equal to 150% of note conversion price ............................... $2,125 $3,185 Bridge II Convertible Secured Promissory Notes; due July 31, 2003; interest rate 12% per annum; convertible into common stock at $0.10 or $0.15 per share; beneficial conversion feature valued at $2,036,200 and $330,000 at September 30, 2003 and December 31, 2002, respectively; Bridge II warrants at an exercise price of $0.15 or $0.20 per share ....................... 3,127 293 Round Valley Capital, LLC $825,500 Promissory Note, including unearned interest dated August 30,2002; interest rate 36% per annum; warrants at an exercise price of $0.20 per share; 711,364 shares of common stock ...................... -- 300 Monsun, AS, $500,000 Promissory Note issued November 1, 2000; interest rate 15% per annum, compounded into principal amount; beneficial conversion feature valued at $125,000; 1st extension of maturity date for issuance of 100,000 warrants at an exercise price of $0.60 per share; 2nd extension of maturity date for the issuance of 200,000 warrants at an exercise price of $0.30 per share; 3rd extension of maturity date for the issuance of 200,000 warrants at an exercise price of $0.70 per share; stock issuance of 200,000 shares of common stock in lieu of default penalty ................................................................................... 618 552 Trek Diagnostic Systems $80,000 Promissory Note issued July 31, 2002; due in equal installments on September 1, 2002 and December 1, 2002 .................................... 40 40 O.P., LLC $29,390 Promissory Note issued May 12, 2003; interest at 7% per annum; monthly principal payment of $1,316 plus interest ................................................. 24 -- Ungaretti and Harris $211,368 Secured Promissory Note issued May 8, 2003; interest at 12% per annum; due September 30, 2003 ......................................................... 145 -- Ernst & Young $30,800 Promissory Note issued July 17, 2003; due December 31, 2003 ............. 31 -- Xillix Technologies Corporation $361,000 Promissory Note issued June 26, 1998; interest rate Canadian Prime plus 6% per annum; represents a debt of AccuMed International ......... 34 34 Western Economic Diversification, $221,000 Promissory Note issued June 1989; no interest; represents a debt of Oncometrics .......................................................... 214 182 ------ ------ $6,358 $4,585 ====== ======
Between March 22, 2002 and June 28, 2002, MDI issued $3,185,000 in series Bridge I Convertible Promissory Notes to accredited investors. The notes bear interest at the rate of 7% per annum and are convertible at any time into the common stock of MDI at a conversion price equal to 75% of the market price of the common stock on the date of conversion. In addition, MDI issued a warrant, which entitled each holder to purchase one share of common stock, at an exercise price of $0.25 per share, for each dollar principal amount of notes. MDI calculated a fair value of $99,950 for these warrants using the fair value interest rate method and recorded this amount as additional interest expense during 2002. At the time of conversion of the note, the holder is entitled to receive a warrant to purchase one share of common stock for each four shares of common stock into which the note converts at an exercise price equal to 150% of the conversion price of the note. MDI has not determined a value for the warrants as of June 30, 2003. Since the conversion price of the note is at a 25% discount to the market price of the common stock of MDI, the holder is considered to have a beneficial conversion feature. MDI determined the value of the beneficial conversion feature to be $1,041,666 and recorded this amount as additional interest expense during 2002. In February 2003, a note holder, NeoMed Innovations III, converted $1,060,000 in principal amount of Bridge I notes into Bridge II notes. The remaining $2,125,000 in principal Bridge I notes remains unconverted and outstanding at September 30, 2003. Management has extended a written offer, dated October 10, 2003, to the Bridge I noteholders to convert their Convertible Promissory Notes and accrued interest into common shares at $0.15 per share. In addition, the Bridge I holders were also offered warrants to purchase one new share for every four shares acquired by the Bridge noteholder upon exercise of such holder's conversion rights under the note. As of November 10, 2003, this offer remained outstanding. 9 Beginning in October 2002, MDI began an issue of up to $4,000,000 in series Bridge II Convertible Promissory Notes to accredited investors. MDI issued $550,000 in Bridge II notes as of December 31, 2002. During the first nine months of 2003, MDI issued an additional $1,858,200 in principal amount of Bridge II notes. The notes bear interest at a rate of 12% per annum payable at the maturity date in kind in the form of shares of common stock of MDI. The Company granted the holders a junior security position in all of its assets. The notes are convertible at any time into the common stock of MDI. The note conversion price and the value of common shares paid in kind as interest for the first $1,000,000 in principal amount of cash subscriptions, determined on a "first come - first served basis," is $0.10 per share. The note conversion price and the value of common shares paid in kind as interest for the remaining $3,000,000 of principal amount of notes in the series is $0.15 per share. The conversion price of the notes issued during 2002 and those issued during the first nine months of 2003 was less than the market price of the common stock when the notes were issued; therefore, the holders are considered to have a beneficial conversion feature. MDI determined the value of the beneficial conversion feature to be $1,706,200 and $330,000 at September 30, 2003 and December 31, 2002, respectively. The value was recorded as a reduction of the debt and will be amortized as additional interest over the life of the note. MDI recorded additional interest expense of $1,652,708 to reflect amortization of the discount during the nine months ended September 30, 2003. The Bridge II notes automatically convert into shares of Common Stock (subject to adjustments for stock splits, etc.) upon a "Qualified Financing Transaction," which means a transaction in which the Company closes a new debt or equity financing prior to the maturity date that results in net proceeds to the Company of at least four million dollars ($4,000,000). At the time MDI completes significant additional funding plans, as outlined in the subscription agreement, each holder of Bridge II notes is entitled to receive a warrant to purchase one share of the common stock of the Company for each four shares of common stock into which the note is convertible at an exercise price of $0.15 per share for notes in the class pertaining to the first $1,000,000 in subscriptions and $0.20 for the remaining $3,000,000 in note principal subscriptions. In September 2003 an amendment to the Bridge II Convertible Promissory Notes was sent to holders requesting an extension of the notes to July 31, 2004. As additional consideration for the extension, holders were offered an increase in the interest rate from 12% to 15%. In addition, an amendment to the indenture also offered an increase in the warrant coverage ratio from 25% to 33%. Subsequent to September 30, 2003, MDI issued additional notes in the Bridge II series. (See Footnote 9: Subsequent Events) On August 30, 2002, MDI issued a Promissory note to Round Valley Capital, LLC ("RVC") in the amount of $825,500 representing $650,000 in cash received by MDI and $175,500 in unearned interest. The note bears a calculated effective interest rate of 36% per annum and is due June 1, 2003. The note is secured by all of the assets of MDI. MDI issued a certificate representing 5,750,000 shares of the common stock of the Company to RVC as collateral for the loan and paid transaction fees including: cash payments of $147,063; 711,364 shares of common stock of MDI; and warrants to purchase 681,818 shares of common stock of MDI at an exercise price of $0.20 per share. MDI recorded the note at a value, net of unearned interest, of $650,000. A fair value of $362,795 was calculated for the shares of common stock of MDI issued to RVC using the market price of the common stock on the date the shares were issued. A fair value of $156,000 was calculated for the warrants using the Black-Scholes valuation method. The total value of the transaction fees was recorded as prepaid financing costs and is being amortized over the life of the note. During 2002, MDI made principal payments against the note of $350,000. RVC declared MDI to be in default under the terms of the note during 2002 and the parties were engaged in litigation and subsequently, settlement negotiations. On April 2, 2003, MDI paid RVC $900,000 in cash in final settlement of the loan, default penalties and to exercise its rights under the asset purchase option agreement. RVC returned the 5,750,000 shares of common stock issued as collateral under the note, 711,364 shares of common stock issued as financing fees, and warrants to purchase 531,818 shares of common stock also issued as financing fees. MDI cancelled the shares of common stock and the warrants. On February 17, 2003, MDI made additional principal payments amounting to $250,000. MDI recorded interest expense of $16,900 and financing costs, including amortization of accrued financing costs, of $1,009,000 during the six-months ended June 30, 2003. In July 2002, MDI agreed to settle a claim brought by Trek Diagnostic Systems, Inc. ("Trek") against AccuMed regarding breach of representation and warranties in a certain agreement under which Trek purchased the microbiology business of AccuMed in 2000. MDI issued a promissory note to Trek in the amount of $80,000, payable in two equal installments on September 1, 2002 and December 1, 2002. MDI made the first payment due on September 1, 2002. MDI did not make the second payment causing a default on the note. Trek has instituted legal action against MDI to obtain payment of the remaining amount due under the note. The unpaid portion of the note accrues interest at the rate of 8% per annum. MDI recorded interest expense related to this note of $2,665 for the nine-months ended September 30, 2003. 10 Specific events of default have occurred on a significant majority of the outstanding notes payable, including the Bridge I, Bridge II and Suzanne M. Gombrich convertible promissory notes, issued by MDI, ranging from failure to make principal payments when due to breach of certain warranties and representations. The notes payable require the holder to notify MDI in writing of a declaration of default at which time a cure period, as specified in each individual note, would commence. There is no guarantee that MDI would be able to cure any event of default if, or when, the holder provides the required written notice. Other than the $618,000 Monsun AS convertible promissory note and the Trek Diagnostics $40,000 note payable, which are the subject of legal actions described in Footnote 10 - Legal Proceedings, MDI has not received any written declarations of default from holders of its outstanding notes payable. The carrying amounts of notes payable approximates fair value at September 30, 2003 and December 31, 2002. Note 7.Stockholders' Equity Summary of the Company's preferred stock capital table as of: September 30, December 31, 2003 2002 --------------- --------------- Shares Issued & Shares Issued & Offering Outstanding Outstanding - -------- --------------- --------------- Series A convertible ....................... 82,655 118,092 Series B convertible, 10% cumulative ....... 799,856 799,856 Series C convertible, 10% cumulative ....... 1,192,833 1,258,833 Series D convertible, 10% cumulative ....... 175,000 175,000 Series E convertible, 10% cumulative ....... 261,277 429,243 --------- --------- Total Preferred Stock ...................... 2,511,621 2,781,024 ========= ========= During the first nine months of 2003 a holder converted 66,000 shares of Series C convertible preferred stock, including cumulative dividends due thereon, into 380,403 shares of common stock. In June 2003, two holders converted 35,437 shares of Series A convertible preferred stock into 15,478 shares of common stock. During the first nine months of 2003 several holders converted 167,966.76 shares of Series E convertible preferred stock, including cumulative dividends due thereon, into 5,133,927 shares of common stock. Summary of Preferred Stock Terms Series A Convertible Preferred Stock Liquidation Value: $4.50 per share Conversion Price: $10.3034 per share Conversion Rate: 0.4367--Liquidation Value divided by Conversion Price ($4.50/$10.3034) Voting Rights: None Dividends: None Conversion Period: Any time--3 years Series B Convertible Preferred Stock Liquidation Value: $4.00 per share Conversion Price: $1.00 per share Conversion Rate: 4.00--Liquidation Value divided by Conversion Price ($4.00/$1.00) Voting Rights: None Dividends: 10%--Quarterly--Commencing March 31, 2001 Conversion Period: Any time Cumulative dividends in arrears at September 30, 2003 were $828,851 11 Series C Convertible Preferred Stock Liquidation Value: $3.00 per share Conversion Price: $0.60 per share Conversion Rate: 5.00--Liquidation Value divided by Conversion Price ($3.00/$0.60) Voting Rights: None Dividends: 10%--Quarterly--Commencing March 31, 2002 Conversion Period: Any time Cumulative dividends in arrears at September 30, 2003 were $685,307 Series D Convertible Preferred Stock Liquidation Value: $10.00 per share Conversion Price: $1.00 per share Conversion Rate: 10.00--Liquidation Value divided by Conversion Price ($10.00/$1.00) Voting Rights: None Dividends: 10%--Quarterly--Commencing April 30, 2002 Conversion Period: Any time--After April 1, 2002 Cumulative dividends in arrears at September 30, 2003 were $335,137 Series E Convertible Preferred Stock Liquidation Value: $22.00 per share Conversion Price: $0.80 per share Conversion Rate: 27.50--Liquidation Value divided by Conversion Price ($22.00/$0.80) Voting Rights: Equal in all respects to holders of common shares Dividends: 10%--Quarterly--Commencing May 31, 2002 Conversion Period: Any time--After December 1, 2002 Cumulative dividends in arrears at September 30, 2003 were $1,011,034 Issuance of Restricted Shares for Services Beginning in 1999, the Company has, at various times, awarded restricted shares of common stock to non-employee consultants for services. Some of the share awards were made for past services and their value was fixed. Other share awards were made as partial consideration for services to be performed under three-year consulting agreements and vest over the life of the agreements. The final measurement date of these shares was determined to be July 2003. A fair value of these shares of $18,250 and $39,000 was calculated at September 30, 2003 and September 30, 2002, respectively, using the Black-Scholes valuation model, and the Company recorded $1,007 as additional expense and $31,000 as reduction of expense during the nine months ended September 30, 2003 and September 30, 2002, respectively. Issuance of Shares for Services In January 2003, MDI issued 1,000,000 shares of common stock in exchange for services to a non-employee professional services firm. MDI calculated a fair value of $100,000 for these shares based on the value of the shares on the date of the issuance and recorded the amount as investor relations expense as of March 31, 2003. In May 2003, MDI issued 875,000 shares of common stock in exchange for services to a non-employee professional services firm. MDI calculated a fair value of $218,750 for these shares based on the market value of the shares on the date they were due and is amortizing the amount over the remainder of the service contract. In June 2003, MDI issued 83,642 shares of common stock to a non-employee service vendor in lieu of payment for unpaid service invoices. MDI valued the shares at $12,463 which represented the amount of the unpaid invoices. In July 2003, MDI issued 1,375,000 shares of common stock to non-employees for past and future financing and consulting services. MDI calculated a fair value of $495,000 for these shares based on the fair market value of the shares on the date they were issued. Of the total amount $207,000 is being amortized over the life of the services contract. In August 2003, MDI issued 170,000 shares of common stock to a non-employee financial consultant for past financing services. MDI valued the shares at $51,000. 12 Issuance of Warrants for Services On April 2, 2003, MDI issued a warrant to Suzanne M. Gombrich, an affiliate, entitling the holder to purchase 1,000,000 shares of common stock of MDI at an exercise price of $0.15 per share. The warrant was issued as additional consideration for a $1,000,000 convertible promissory note issued on the same date. MDI valued the warrants at $270,000 using the Black-Scholes valuation model and recorded the amount as a current quarter administrative expense. In August 2003, MDI issued 1,100,000 warrants with an exercise price of $0.17 per share to a non-employee financial consultant for past financial services. MDI valued the warrants at $341,000 using the Black-Scholes valuation model and recorded the amount as a current quarter administrative expense. In September 2003, MDI issued 1,335,000 warrants with an exercise price of $0.20 per share to non-employee financial consultants for past financial services. MDI valued the warrants at $347,100 using the Black-Scholes valuation model and recorded the amount as a current quarter administrative expense. In September 2003, MDI issued 500,000 warrants with an exercise price of $0.17 per share to a non-employee consultant in lieu of payment for future services. MDI valued the warrants at $150,000 using the Black-Scholes valuation model and is amortizing the amount over the twelve month period of the consulting term. Application of Black-Scholes Valuation Model In applying the Black-Scholes valuation model, the Company has used an expected dividend yield of zero for both periods, a risk-free interest rate of 4.5% and 6% for the 2003 and 2002 periods, respectively, a volatility factor of 198% and 90% for the 2003 and 2002 periods, respectively, and a fair value of the underlying common shares of closing market price on the date of the grant for both periods. The expected life equaled the term of the warrants, options, or restricted shares. Note 8. Equity Incentive Plan and Employee Stock Purchase Plan On May 25, 1999, stockholders approved the establishment of the 1999 Equity Incentive Plan effective as of June 1, 1999. The Plan provides that the Board may grant various forms of equity incentives to directors, employees, and consultants, including but not limited to Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, and Restricted Stock Awards. Grants under the Plan are exercisable at fair market value determined as of the date of grant in accordance with the terms of the Plan. Grants vest to recipients immediately or ratably over periods ranging from two to five years, and expire five to ten years from the date of grant. On May 23, 2000, stockholders approved Amendment No. 1 to the Plan, which increased the number of shares of common stock allocated for use in the Plan from 2,000,000 shares to 3,000,000 shares. On June 21, 2002, stockholders approved an Amendment to the Plan, which increased the number of shares allocated for use in the Plan from 3,000,000 shares to 5,500,000 shares. The Board of Directors has also granted options to purchase common stock of MDI, which are not covered by the terms of the Plan. MDI applies APB Opinion No. 25 and related interpretations in accounting for options granted to employees under the Equity Incentive Plan. No compensation cost was recorded during 2003 or 2002 for options granted to employees as the exercise price approximated the fair value of the underlying common stock on the date of the grant. Had stock options been accounted for under the fair value method recommended by FAS 123, the Company's net loss applicable to common shareholders would have been changed to the pro forma amounts indicated below: 13
For the nine months ended For the three months ended September 30, September 30, ------------------------- -------------------------- 2003 2002 2003 2002 ------- -------- ------- ------- (in thousands except for per share amounts) Net loss applicable to common shareholders as reported .................... $(9,235) $(11,063) $(4,178) $(3,638) Deduct: Total stock-based compensation expense determined under the fair value based method for all awards, net of related taxes . 33 (269) (16) (233) ------- -------- ------- ------- Pro forma net loss applicable to common shareholders ......................... $(9,202) $(11,332) $(4,194) $(3,871) ======= ======== ======= ======= Basic loss per share applicable to common shareholders - as reported .................. $ (0.23) $ (0.43) $ (0.11) $ (0.14) ======= ======== ======= ======= Basic loss per share applicable to common shareholders - pro forma ............. $ (0.23) $ (0.44) $ (0.11) $ (0.15) ======= ======== ======= =======
The fair value for these options was estimated at the date of the grant using a Black-Scholes option pricing model with the following weighted average assumptions: risk-free interest rates of 4.5% and 6% for the 2003 and 2002 periods, respectively; dividend yields of zero; volatility factors of the expected market price of the Company's common stock of 198% and 90% for both years and a weighted average expected life of the options of 2.5 - 5 years. A summary of the Company's stock option activity, during the nine-month periods ended September 30, 2003 and 2002, and related information follows:
Option Plan Shares -------------------------- 2003 2002 --------- --------- Outstanding: December 31, 2002 and 2001, respectively ...... 3,507,517 3,792,496 Granted through September 30, .......................... 600,000 286,833 Exercised through September 30, ........................ -- (361,000) Forfeited - assumed in acquisition through September 30, (17,035) (311,220) Forfeited through September 30, ........................ (353,500) (289,000) --------- --------- Outstanding: September 30, 2003 and 2002, respectively ..... 3,736,982 3,118,109 ========= ========= Exercisable at September 30, 2003 .......................... 2,643,314 =========
Note 9.Subsequent Events Bridge II Financing Beginning in October 2002, MDI began an issue of up to $4,000,000 in series Bridge II Convertible Promissory Notes to accredited investors. The notes bear interest at 12 % per annum payable at maturity date in kind in the form of shares of common stock and were due July 31, 2003. The notes are convertible at any time into the common stock of MDI. The note conversion price and the value of common shares paid in kind as interest for the first $1,000,000 in cash subscriptions, determined on a "first come - first served basis," is $0.10 per share. The note conversion price and the value of common shares paid in kind as interest for the remaining $3,000,000 of principal amount of notes in the series is $0.15 per share. MDI granted each note holder the right to receive a private warrant to purchase one share of the common stock of MDI for each dollar of principal amount of notes held at an exercise price of $0.15 per share. The warrants are not issueable until such time as MDI completes significant additional financing plans. MDI granted a junior security position in all of the Company's assets to the holders of the Bridge II convertible promissory notes. The Bridge II notes automatically convert into shares of Common Stock (subject to adjustments for stock splits, etc.) upon a "Qualified Financing Transaction," which means a transaction in which the Company closes a new debt or equity financing prior to the maturity date that results in net proceeds to the Company of at least four million dollars ($4,000,000). Through September 30, 2003, MDI issued $1,858,200 in principal amount of Bridge II convertible promissory notes in exchange for cash. Between October 1, 2003 and November 10, 2003, MDI issued an additional $122,000 in principal amount of Bridge II convertible promissory notes in exchange for cash. In September 2003 an amendment to the Bridge II Convertible Promissory Notes was sent to holders requesting an extension of the notes to July 31, 2004. As additional consideration for the extension, holders were offered an increase in the interest rate from 12% to 15%. In addition, an amendment to the indenture offered an increase in the warrant coverage ratio from 25% to 33%. Warrants On July 18, 2003, Mr. Milley, a director, Azimuth Corporation and Cadmus Corporation, agreed to cancel seven warrants held by Azimuth and one warrant held by Cadmus, which entitled the holders to purchase a total of 3,125,000 shares of common stock at various exercise prices between $0.01 and $1.25 per share. The warrants, issued between 14 December 1999 and August 2001, contained anti-dilution clauses which required MDI to increase the number of shares of common stock the holders were entitled to purchase under the warrants by approximately 1,500,000 shares as of the date of the agreement, with commensurate adjustments in individual exercise prices so that gross proceeds to the Company from exercise of the warrants remained the same. These anti-dilution provisions could have required the Company to make additional adjustments in shares and exercise prices in the future based on the Company's issuance of debt or equity instruments at prices below the adjusted exercise prices of these warrants. In consideration for the parties' agreement to cancel these warrants, including their individual anti-dilution clauses, and the forgiveness of approximately $120,000 currently owing to Azimuth and Cadmus, MDI agreed to issue a new five-year warrant entitling the holders to purchase 6,500,000 shares of common stock at an exercise price of $0.30 per share. MDI also agreed to issue a 120- day warrant entitling the holder to purchase 500,000 shares of common stock at an exercise price of $0.30. Management believes that the Company will derive significant additional benefits in the future as a result of the elimination of the anti dilution provisions in the original warrants. Although an agreement has been reached in principal between the parties, no definitive agreement has yet been signed. MDI is currently awaiting receipt of final signed documents. Note 10. Legal Proceedings On July 31, 2002, MDI entered into a settlement and mutual release agreement with Trek Diagnostic Systems, Inc. ("Trek") related to a claim of breach of representations and warranties included in an agreement under which AccuMed sold its microbiology business and related assets to Trek in 1999. Under the settlement agreement, MDI executed an $80,000 promissory note in favor of Trek. The note required principal payments of $40,000 each on September 1 and December 1, 2002. MDI made the initial payment and Trek filed suit against MDI (Court of Common Pleas Cuyahoga County, Ohio (Case No. CV 03 492582)) on January 23, 2003 to collect the remaining $40,000 plus interest at 8% per annum and legal and other costs. At December 31, 2002, MDI accrued the remaining amount due on the note. On April 18, 2003, judgment was entered against MDI in the amount of $40,000 plus interest. On November 5, 2003, the Circuit Court of Cook County ordered that MDI's bank turn over to TREK $25,692.36, which had been residing in that bank account. Management is currently negotiating with Trek on the balance to resolve this matter. On March 28, 2003 The Cleveland Clinic Foundation ("Clinic") filed suit against MDI (United States District Court for the Northern District of Ohio, Easter Division, (Case No. 1:03CV0561)) seeking approximately $315,000 plus interest and attorney fees and costs. The sum in question pertains to remaining unpaid fees for certain clinical trial work conducted by the Clinic in the Peoples Republic of China ("China Study") on behalf of MDI. On December 31, 2002, MDI recorded the full amount owing to the Clinic as a liability in its accounts. On October 22, 2003, MDI and the Clinic entered into a Revised Settlement Agreement and Mutual Release. MDI agreed to pay the sum of $240,000 to the Clinic which will be held in escrow pending the return of MDI's instruments and computer equipment used in the China Study and MDI's successful ability to access available and uncorrupted clinical trial data contained therein. If the China Study data is available, the Clinic agrees to provide all hard copy documentation related to the China Study and to complete a review and analysis of the data in a timely manner. If the data is not available, MDI's payments will be returned to MDI and the lawsuit will go forward. At that point MDI will actively defend itself based on the Clinic's failure to deliver the data required under the original China Study agreement. On January 2, 2003, Bowne of Chicago, Inc. ("Bowne") filed suit against MDI (Circuit Court of Cook County, Illinois (Case No. 03 L 000009)) claiming approximately $342,000, plus interest and costs, related to financial printing service fees provided to MDI by Bowne during the period October 25, 2001 through November 7, 2002. While MDI is actively defending itself against the suit claiming the charges for printing services provided during the period mentioned above were excessive, management has taken a conservative position and recorded the entire amount of the Bowne invoices as outstanding accounts payable on the records of MDI. As of December 31, 2002 and September 30, 2003, management and its counsel are unable to determine what the outcome of this litigation might be. 15 On January 9, 2003, Monsun, AS ("Monsun") filed suit against Peter Gombrich, MDI's Chairman and CEO, (United States District Court for the Northern District of Illinois Eastern Division (Case No. 03C 0184)) claiming damages in excess of $500,000 plus attorneys' fees and costs, and alleging breach of a Guaranty Agreement and a Letter Agreement signed by Mr. Gombrich in conjunction with Monsun's grant of an extension in the maturity date of a convertible promissory note in the principal amount of $500,000 issued by MDI on November 1, 2000. Monsun claims that Mr. Gombrich is obligated under the Guaranty Agreement to pay all monies owed by MDI under the convertible promissory note. MDI has recorded the principal amount of the note plus accrued and unpaid interest to December 31, 2002 as a note payable on its records. Regarding the Letter Agreement, Monsun claims that Mr. Gombrich was obligated to transfer to Monsun 200,000 registered shares of common stock of MDI held by Mr. Gombrich. Since Mr. Gombrich's potential liability in the suit, including delivery of 200,000 registered shares of MDI's common stock, is the result of the failure of MDI to pay the principal amount of its convertible promissory note when due, the Board of Directors has agreed that MDI will assume responsibility for Mr. Gombrich's obligations under the Guaranty Agreement and Letter Agreement, including legal costs. Regarding the claim for breach of the Guaranty Agreement, counsel for Mr. Gombrich has presented a settlement proposal. Monsun, counsel for Mr. Gombrich and the Company's counsel continue to discuss a settlement proposal, and management and counsel are unable to determine the result of this claim. With respect to the claim for breach of the Letter Agreement, on November 2003 Monsun and Mr. Gombrich reached a settlement agreement. In November 2002 and prior to the litigation, the Board of Directors approved the issuance of 200,000 shares of MDI's common stock to Monsun to satisfy Mr. Gombrich's alleged obligation under the Letter Agreement. The terms of the Letter Agreement stated that Monsun was to ultimately receive registered shares of MDI's common stock. However, MDI issued the shares of its common stock to Monsun with a restrictive legend which permits their sale only in compliance with Rule 144 of the Securities Act of 1933, as amended. Under the terms of the settlement agreement, Gombrich and/or MDI must either register the 200,000 shares previously transferred to Monsun or transfer 200,000 registered shares to Monsun on or before March 31, 2004. If Mr. Gombrich or MDI transfer additional shares, Monsun is required to return the previously transferred shares. MDI is a defendant in several lawsuits brought by current or former unsecured creditors to collect past due amounts for goods and services. MDI has recorded the amounts due in its records and is attempting to settle these suits and unfiled claims. MDI is a defendant in several legal actions brought by former employees seeking to collect amounts due for unpaid wages. MDI has recorded the amounts due in its records and is attempting to settle these actions and in some cases it is contesting such actions. In May 2003, the Company, together with its subsidiaries, AccuMed International, Inc. ("Accumed") and Oncometrics Imaging Corp. ("Oncometrics"), filed suit against MonoGen, Inc. ("MonoGen") and Norman J. Pressman, Docket No. 03 CH 08532 (Circuit Court of Cook County, Illinois). This suit arose out of two license agreements, one between AccuMed and MonoGen, and the other between Oncometrics and MonoGen, in which the rights to limited use of certain intellectual property were granted to MonoGen in return for one-time license fee payments totaling $500,000 (the "Agreements"). At the time that the Agreements were entered into, the Company had not yet acquired AccuMed and Oncometrics. A portion of the intellectual property subject to the Agreements had originally been licensed from the British Columbia Cancer Agency ("BCCA"). Pressman was the President of AccuMed and Oncometrics when the Agreements were negotiated and executed. Shortly after the Agreements were signed, Pressman became President of MonoGen. The Complaint filed in this case alleged that certain rights to the subject intellectual property were transferred to MonoGen at a below-market price. The Complaint also asserted that AccuMed and Oncometrics may not have obtained the requisite consent of BCCA to the Agreements. The Complaint also claims that, to the extent BCCA's consent was required, Pressman breached his fiduciary duties to AccuMed and Oncometrics by failing to obtain such consent, and also by negotiating below-market license fees with his future employer. The Company's claims against MonoGen were dismissed from this action. However, the Company's claims against Pressman remain pending. In June 2003, the Court dismissed the Company's request for an injunction against the defendants. This denial does not affect the Company's rights to pursue permanent injuntive relief at the conclusion of the case, if such is warranted. A Second Amended Verified Complaint was filed in this case on November 14, 2003. On November 20, 2003, AccuMed and Oncometrics sent termination notices to MonoGen with respect to the licenses previously granted by them to MonoGen. At the same time, the Company advised BCCA of its plan to settle directly with BCCA any differences it may have with BCCA in regard to the MonoGen licenses. The failure of the Company to negotiate a favorable settlement with BCCA in regard to any such differences could have adverse effect on certain limited aspects of the Company's business. On April 14, 2003, the Company received a notification from the attorney for Dr. Bruce Patterson, M.D., Ph.D, a licensor of the Company under the License and Development Agreement covering certain HPV technology, which forms the basis for our In-Cell HPV test, indicating that the licensor intended to terminate the license in accordance with a specific clause of the license, which permits termination in the event the Company makes an assignment for the benefit of creditors or bankruptcy, or otherwise relinquishes or loses control of all its assets. On April 15, 2003, we informed the attorney 16 that the facts used by the licensor to invoke the termination right were incorrect and that we are still in control of all of our assets and that such assets are pledged as security under debt instruments and that such pledges are not included under events which would permit the licensor to terminate the license. We, and our counsel, believe that MDI would prevail should the licensor attempt to pursue a termination action. We are also engaged in a dispute with the licensor over completion of the third milestone of the license under which completion requires process and procedure verification by an independent third party. This verification requirement has not been satisfied as yet. On July 2, 2003, the licensor and his business, Inviron, Inc., filed suit against MDI (Circuit Court of Cook County, Illinois (Case No. 03 L007995)), claiming a total of $143,556.97 due under two separate contracts. The parties are in settlement discussions to resolve all outstanding issues. 17 Item 2. Management's Discussion and Analysis or Plan of Operation Forward-Looking Statements Certain statements contained in this discussion and analysis of financial condition and results of operations that are not related to historical results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are predictive, that depend upon or refer to future events or conditions, or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," "hopes," and similar expressions constitute forward-looking statements. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, or possible future actions by us are also forward-looking statements. These forward-looking statements are based on beliefs of our management as well as current expectations, projections and assumptions currently available to the Company and are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or those anticipated. These risks are described more fully in our most recent Annual Report on Form 10-K under the caption of Risk factors Item 1 and in subsequent reports filed with the Securities and Exchange Commission. Should one or more of those risks or uncertainties materialize or should underlying expectations, projections and assumptions prove incorrect, actual results may vary materially from those described. Those events and uncertainties are difficult to predict accurately and many are beyond our control. We assume no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date of these statements. The following discussion and analysis should be read in conjunction with our consolidated financial statements presented in Part I, Item 1 of this quarterly report and our consolidated financial statements and Management' Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the year ended December 31, 2002. Significant Accounting Policies Use of Estimates. The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Revenue Recognition. The Company recognizes revenue upon shipment of a product or license to customers and no remaining Company obligations or contingencies exist, or in the case of sales of software by its wholly owned subsidiary, Samba, upon shipment if persuasive evidence of an arrangement exists; sufficient vendor-specific objective evidence exists to support allocating the total fee to all elements of the arrangement; the fee is fixed or determinable; and collection is probable. Revenue from ongoing client maintenance is recognized ratably over the post-contract support term, which is generally twelve months. Revenue from training services and professional services is recognized when the service is completed. Revenue from implementation and installation services is recognized using the percentage of completion method. Revenue from prepayments under licenses is recognized over the license period. Samba calculates percentage of completion based on the estimated total number of hours of service required to complete an implementation project and the number of actual hours of service rendered. Implementation and installation services are generally completed within 120 days. Licenses, Patents, Technology and Goodwill. Licenses, patents, and purchased technology are recorded at their acquisition cost. Costs to prepare patent filings are expensed when incurred. Costs related to abandoned patents are written off at the time of abandonment. Amortization is begun as of the date of acquisition or upon the grant of the final patent. Costs are amortized over the asset's useful life, which ranges from two to seventeen years. The Company assesses licenses, patents, and technology quarterly for impairment. 18 Goodwill. The Company has adopted FAS 142, which sets forth guidelines for discontinuing periodic goodwill amortization costs in results of operations and for establishing an annual goodwill impairment review and related net realizable value asset write-down methodology. Research and Development Costs. Research and development costs are charged to operations as incurred. Molecular Diagnostics, Inc. conducts a portion of its research activities under contractual arrangements with scientists, researchers, universities, and other independent third parties. Foreign Currency Translation. The functional currency of the Company's foreign operations is the local currency. Accordingly, all assets and liabilities are translated into United States dollars using period-end exchange rates, and all revenues and expenses are translated using average exchange rates during the period. The amount of foreign currency translation is not material to the results of operations and the financial position of the Company. Other Comprehensive Income (Loss). Translation adjustments related to the Company's foreign operations are included in other comprehensive loss and reported separately in stockholders' equity (deficit). Stock Compensation. As permitted by the Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation (SFAS 123), Molecular Diagnostics, Inc. uses the intrinsic value method to account for stock options as set forth in Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (APB 25). Impairment. At each balance sheet date or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, management of the Company evaluates recoverability of such assets. An impairment loss is recognized if the amount of undiscounted cash flows is less than the carrying amount of the asset in which case the asset is written down to fair value. The fair value of the asset is measured by either quoted market prices or the present value of estimated expected future cash flows using a discount rate commensurate with the risks involved. Application of Black-Scholes Valuation Model. In applying the Black-Scholes valuation model, we have used an expected dividend yield of zero, a risk-free interest rate of 4.5% and 6% for 2003 and 2002, respectively, a volatility factor of 198% and 90% for 2003 and 2002, respectively, and the closing market price of the underlying common stock on the date of the grant. There were 600,000 in option grants during the first nine months of 2003. The expected life equaled the term of the warrants, options, or restricted shares. Overview of Molecular Diagnostics The science of medical diagnostics has advanced significantly during the past decade. Much of this advance has come as a result of new knowledge of the human genome and related proteins, which form the foundation of cell biology and the human body. Our goal is to utilize this research as a base to develop screening and diagnostic testing products for cancer and cancer-related diseases. We believe that the success of these products will improve patient care through more accurate test performance, wider availability and cost effective service delivery. We are developing an initial series of products to address these criteria including sample collection devices, chemical and biological tests, and analytical instruments and related software. Our strategy is to develop products through internal development processes, strategic partnerships, licenses and acquisitions of companies. This strategy has required and will continue to require additional capital. As a result, we will incur substantial operating losses until we are able to successfully market some, or all, of our products. Results of Operations Revenue Our revenue for the nine-month period ended September 30, 2003 totaled $1,280,000, representing a decrease of $173,000, or 11.9%, over revenue of $1,453,000 for the nine-month period ended September 30, 2002. The 2003 comparative revenue decrease results primarily from one-time revenue recognition during the first quarter of 2002 of $298,000 from the sale of a three-year irrevocable, worldwide, royalty-free license for full access to Samba's image 19 analysis software and development tools to Ventana Medical Systems, Inc. The remaining increase represents gains in new customer AcCell instrument sales and installations. Revenue of $262,000 for the three months ended September 30, 2003 represented a decrease of $33,000, or 11.2%, over revenue for the same period in 2002. This resulted from a decrease in MDI instrument related revenues. Revenues from our European subsidiary, Samba, are derived from the sale of proprietary Telemedicine software and software consulting services. Samba conducts its operations in local currency, the Euro. We convert the local currency into U.S. Dollars for consolidated reporting purposes. Samba's revenue recognition is also subject to the timing of receipt and completion of customer contracts from period to period. We may experience quarter-to-quarter and year-to-year variability in revenues as a result of these contract-timing issues until we begin to market some or all of our other products. Operating Cost of Revenues Cost of revenues for the nine months ended September 30, 2003 totaled $667,000, an increase of $23,000 from the same period in 2002. No cost of revenues attributable to the Ventana license sale was recorded since related research and development costs related thereto were expensed as incurred in prior years. Cost of revenues for the three months ended September 30, 2003 totaled $159,000, a decrease of $3,000 or 1.9%, from the same period in 2002. The decrease was the result of a reduction in MDI instruments sold during the period. Research and Development We devote a substantial amount of our resources to research and development ("R&D") related to new products, including markers, tests, instruments and software applications, as well as modifications and refinements of our existing products. R&D expenses decreased $2,954,000 and $738,000 for the nine-month and three-month periods ended September 30, 2003 to $448,000 and $129,000, a decrease of 86.8% and 85.1%, respectively, over the comparable prior year periods. These reductions were the result of reduced operating capacity due to capital and liquidity constraints. R&D expenses consist of the following: o costs related to specific development programs with scientists and researchers at universities and hospitals; o full scale device development contracts begun during 1999 with industrial design and manufacturing companies covering the disposable and instrument components of the InPath System; o payments to medical and engineering consultants for advice related to the design and development of our products and their potential uses in the medical technology marketplace; o instrumentation, disposables, clinical consumables, clinical supplies and regulatory costs to develop clinical trial reference laboratories and to recruit and test patients in support of our various Food and Drug Administration ("FDA") clinical trials, and o payroll-related costs for in-house engineering, scientific, laboratory, and software development activities; and research management staff. Selling, General and Administrative Selling, general and administrative expenses ("SG&A") decreased $463,000 and increased $749,000 for the nine-month and three-month periods ended September 30, 2003 to $5,699,000 and $2,489,000, a decrease of 7.5% and increase of 43.0% over the same periods ended September 30, 2002, respectively. This decrease is the result of reduced operating capacity due to capital and liquidity constraints, and a reduction in legal expenses due to the one-time recording of $675,000 in legal costs related to a litigation settlement during the first quarter of 2002. The increase in the expenses for the three-month period is related primarily to an increase of $1,299,000 in financing costs to raise capital 20 Significant components of SG&A are compensation costs for executive, sales and administrative personnel, professional fees primarily related to legal and accounting and consulting services, travel costs, printing costs, fees for public and/or investor relations services, insurance premiums, facilities and office expenses, marketing related costs, and amortization/depreciation charges, many of which showed significant declines due to the reduction in overall operations, which began during the last quarter of 2002. Other Income and Expense Interest Expense Interest expense, including interest expense to related parties, increased $1,172,000 and $761,000 for the nine-month and three-month periods ended September 30, 2003 to $2,635,000 and $1,343,00, an increase of 80.1% and 130.8% over the same periods ended September 30, 2002, respectively. This increase was mainly related to the issuance of the interest bearing Bridge I and Bridge II convertible promissory notes. Bridge I convertible promissory notes, in principal amounts totaling $2,125,000 and issued between March 22, 2002 and June 25, 2003, and Bridge II convertible promissory notes, in principal amounts totaling $3,468,200, and issued between October 29, 2002 and September 30, 2003 were outstanding for all or some of the nine months ended September 30, 2003. See further discussion in the preceding Notes To Consolidated Financial Statements -- Note 6. Also, accrued interest expense resulting from related party convertible notes payable is included in interest expense -- related party. Other Income and Expense, Net For the nine months ended September 30, 2002, we recorded a $150,000 gain from the settlement of the SpectRx litigation during the first quarter 2002. Related SpectRx settlement legal expenses are included in selling, general and administrative expenses for the period ended September 30, 2002. Other Income for the nine months ended September 30, 2003 totaled $47,000 and relates to vendor restructuring settlements during the period. Net Loss The net loss for the nine-month and three-month period ended September 30, 2003 before preferred dividends totaled $8,122,000 and $3,817,000 compared with $10,067,000 and $3,056,000 for the same periods in 2002, a decrease of $1,945,000 and a increase of $761,000 or a decrease of 19.3% and a increase of 24.9%, respectively. The decrease for the nine-month period was primarily the result of reduced operating capacity due to capital and liquidity constraints. The increase for the three-month period was primarily the result of an increase in financing costs. In addition, cumulative dividends on the outstanding Series B convertible preferred stock through Series E convertible preferred stock totaled $1,113,000 and $361,000 for the nine-month and three-month periods ended September 30, 2003 compared with $996,000 and $582,000 for the same periods in 2002, respectively. The combined net loss applicable to common stockholders for the nine and three-month periods ended September 30, 2003 of $9,235,000 and $4,178,000 or $0.23 and $0.11 per share, on 40,191,128 and 38,858,622 weighted average common shares outstanding, respectively, compared with the net loss and net loss available to common stockholders for the nine and three-month periods ended September 30, 2002 of $11,063,000 and $3,638,000 or $0.43 and $0.14 per share, on 25,956,783 and 26,550,822 weighted average common shares outstanding. At September 30, 2003, cumulative dividends on the outstanding Series B convertible preferred stock, Series C convertible preferred stock, Series D convertible preferred stock and Series E convertible preferred stock totaled $2,860,329. The weighted average shares outstanding during the quarter ended September 30, 2003 reflect the conversion of Series B, Series C, and Series E convertible preferred stock during 2002 and Series A, Series C, and Series E convertible preferred shares during the nine months ended September 30, 2003. It also reflects, 5,750,000 shares of common stock issued to RVC as additional loan collateral in September 2002. The shares were returned to MDI and cancelled in June 2003. Liquidity and Capital Resources R&D, clinical trials and other studies of the components of our InPath System, conversions from designs and prototypes into product manufacturing, initial sales and marketing efforts, medical consultants and advisors, and research, administrative, and executive personnel are and will continue to be the principal basis for our cash 21 requirements. We have provided operating funds for the business since its inception through private offerings of debt and equity to U.S. and foreign accredited investors. We will be required to make additional offerings in the future to support the operations of the business until some or all of our products are introduced into the market. We used $2,788,000 and $3,721,000 for the nine months ended September 30, 2003 and 2002, respectively, in operating activities. At September 30, 2003 we had cash on hand of $124,000, an increase of $82,000 compared to the $42,000 cash on hand at December 31, 2002. This increase can be attributed to new capital funding from Bridge II notes issued during the period and improved collection of Samba receivables offset by current operating expenses and payments of certain liabiliites. During the first quarter of 2003, we issued $350,000 in Bridge II convertible notes in exchange for cash. The notes were issued under the same terms as all other previous Bridge II notes. We used $250,000 of the proceeds to make principal and interest payments on the RVC loan. During the second quarter of 2003, we issued an additional $791,100 in Bridge II convertible notes in exchange for cash or services. A Bridge II note in the amount of $15,000 was issued to Northlea Partners, Ltd. on May 1, 2003. Dr. John Abeles, one of our directors, serves as the managing partner of Northlea Partners, Ltd. The note was issued under the same terms and conditions as all other Bridge II notes. We used the proceeds of the notes issued during the second quarter to meet current operating needs and to make payments to our previous independent auditors for past services and to our current independent auditors for services related to the audit of our financial statements for the year ended December 31, 2002 and the preparation of our Annual Report on Form 10-K as filed with the Securities and Exchange Commission at the end of the second quarter of 2003. During the third quarter of 2003, we issued an additional $717,100 in Bridge II convertible notes in exchange for cash or services. We used the proceeds of the notes issued during the third quarter to meet current operating needs and to pay some vendor past due amounts and settlements. During the first quarter of 2003, Mr. Gombrich, our Chairman and CEO, loaned the Company an additional $115,000 to meet some of our operating needs and was owed $242,000 at the end of the quarter. During the second quarter of 2003, Mr. Gombrich loaned an additional amount of $20,000 and was repaid $101,000 with an ending loan balance of $141,000. During the third quarter of 2003, Mr. Gombrich advanced an additional amount of $103,000 in expenses and was repaid $104,000 with an ending balance of $140,000. In March 2003, an affiliate, Suzanne M. Gombrich, the wife of our Chairman, loaned the Company $100,000 in cash, reflecting the initial proceeds of a $1,000,000 convertible promissory note described in the following paragraph. We used the $100,000 to buy the purchase option related to the RVC loan settlement. On April 2, 2003, MDI issued a $1,000,000 Convertible Promissory Note to Suzanne M. Gombrich, in exchange for $900,000 in cash. The April note included the $100,000 advance loan proceeds described in the preceding paragraph. The note bears interest at the rate of 12% per annum and is convertible into our common stock at a conversion price of $0.10 per share. As additional consideration, we granted the holder a warrant to purchase 1,000,000 shares of our common stock at an exercise price of $0.15 per share. We also granted the holder a first priority security interest in all of our assets. We used the $900,000 cash proceeds to make the required payment to exercise the purchase option in conjunction with the final settlement of the loan with Round Valley Capital, LLC. On August 30, 2002, we issued a promissory note to Round Valley Capital, LLC ("RVC") in the amount of $825,500 representing $650,000 in cash received in exchange for the note and $175,500 in unearned interest. The note was due June 1, 2003 and bore interest at a calculated rate of 36% per annum. The note was secured by all of our assets. We paid transaction fees in cash of $147,063, issued RVC 711,364 shares of our common stock and warrants to purchase 681,818 shares of our common stock at an exercise price of $0.20 per share. We also issued a certificate representing 5,750,000 shares of our common stock as additional collateral for the loan. As of December 31, 2002, we had made principal and interest payments against the note of $350,000 and $59,500, respectively. As a result of issues over the value of collateral, RVC declared the note to be in default and attempted to foreclose on our assets and sell them at auction. We instituted legal action against RVC, halting the foreclosure and asset sale, and immediately entered into settlement negotiations. In early December of 2002, we reached a settlement agreement with RVC under which we were required to pay the remaining $300,000 principal balance of the note plus an additional amount of $115,000, representing the remaining unearned interest on the note, by January 4, 2003. The agreement provided that if the payment due on January 4, 2003 was not made in a timely manner, a default penalty would be assessed each week payment was not made until a final payment amounting to $950,000 would be due on February 19, 2003. Because of capital and liquidity constraints, we were not able to make the payment due on January 4, 2003 and made no further payments until February 22 17, 2003, when we paid RVC $250,000 leaving a remaining balance due under the settlement agreement of $700,000. At the end of February RVC proceeded with foreclosure against our assets. At that time we agreed to pay RVC $100,000 for an option to repurchase our assets at any time prior to the close of business on April 2, 2003. The option prevented RVC from selling the assets to any party other than us before that date. We used the proceeds of Bridge II convertible promissory notes issued in February, as described above, to make the $250,000 payment to RVC. On April 2, 2003, we paid RVC $900,000 as a final settlement and to exercise the purchase option to reacquire all of our assets. We used the proceeds of a convertible promissory note issued to an affiliate, as described above, to make the final payment to RVC. In conjunction with this final payment, RVC returned 5,750,000 shares of our common stock issued as collateral, 711,364 shares of our common stock and warrants to purchase 531,818 shares of our common stock issued to RVC as payment for transaction fees. We cancelled the returned shares of common stock and warrants. Our capital expenditures were approximately $18,000 for the nine months ended September 30, 2003, a reduction of $70,000, or 79.5% from the prior year period's $88,000. Capital expenditures are defined as disbursements for laboratory equipment, leasehold improvements, software, and furniture/fixtures with a purchase price in excess of $1,000 per item and useful life in excess of one year. The decrease in 2003 capital expenditures resulted from a reduction of laboratory and computer equipment and software purchases in support of our product development and research efforts in order to conserve cash through our private placement and bridge financings. Specific events of default have occurred on a significant majority of our outstanding notes payable, including $2,125,000 of Bridge I convertible promissory notes, $3,468,200 of Bridge II convertible promissory notes and the $1,000,000 Suzanne M. Gombrich convertible promissory note, ranging from failure to make principal payments when due to breach of certain warranties and representations. The notes payable require the holder to notify us in writing of a declaration of default at which time a cure period, as specified in each individual note, would commence. There is no guarantee that we would be able to cure any event of default if, or when, the holder provides the required written notice. Other than the $618,000 Monsun AS convertible promissory note and the $40,000 Trek Diagnostics note payable, which are the subject of legal actions described in Footnote 10 - Legal Proceedings, we have not received any written declarations of default from holders of our outstanding notes payable. Our operations have been, and will continue to be, dependent upon management's ability to raise operating capital in the form of debt or equity. We have incurred significant operating losses since the inception of our business. We expect that significant ongoing operating expenditures will be necessary to successfully implement our business plan and develop, manufacture and market our products. As a result of capital and liquidity constraints, we significantly reduced our staff and all other operating expenditures beginning in the last quarter of 2002 and continuing through most of the second quarter of 2003. We began to reestablish our operations at the end of the second quarter of 2003. These circumstances raise substantial doubt about our ability to continue as a going concern. There can be no assurance that we will be able to obtain additional capital to meet our current operating needs or to complete pending or contemplated licenses or acquisitions of technologies. If we are unable to raise sufficient adequate additional capital or generate profitable sales revenues, we may be forced to continue our operations at a reduced level, substantially delaying product research and development, clinical trials, market introduction of some of our products and other activities and may even be forced to cease operations. ITEM 3. CONTROLS AND PROCEDURES EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES Our principal executive officer and principal financial officer have concluded, based upon their evaluation as of September 30, 2003, that our disclosure controls and procedures (as defined in Rules 13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1934, as amended) are effective to ensure that information required to be disclosed by MDI in the reports filed or submitted by us under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. There have been no significant changes in our internal controls or in other factors that could significantly affect our internal controls subsequent to the date we completed our evaluation. There were no discoveries of any significant deficiencies or material weaknesses in such controls that would require the Company to take corrective action. 23 Part II. Other Information Item 1. Legal Proceedings On July 31, 2002, MDI entered into a settlement and mutual release agreement with Trek Diagnostic Systems, Inc. ("Trek") related to a claim of breach of representations and warranties included in an agreement under which AccuMed sold its microbiology business and related assets to Trek in 1999. Under the settlement agreement, MDI executed an $80,000 promissory note in favor of Trek. The note required principal payments of $40,000 each on September 1 and December 1, 2002. MDI made the initial payment and Trek filed suit against MDI (Court of Common Pleas Cuyahoga County, Ohio (Case No. CV 03 492582)) on January 23, 2003 to collect the remaining $40,000 plus interest at 8% per annum and legal and other costs. At December 31, 2002, MDI accrued the remaining amount due on the note. On April 18, 2003, judgment was entered against MDI in the amount of $40,000 plus interest. On November 5, 2003, the Circuit Court of Cook County ordered that MDI's bank turn over to TREK $25,692.36, which had been residing in that bank account. Management is currently negotiating with Trek on the balance to resolve this matter. On March 28, 2003 The Cleveland Clinic Foundation ("Clinic") filed suit against MDI (United States District Court for the Northern District of Ohio, Easter Division, (Case No. 1:03CV0561)) seeking approximately $315,000 plus interest and attorney fees and costs. The sum in question pertains to remaining unpaid fees for certain clinical trial work conducted by the Clinic in the Peoples Republic of China ("China Study") on behalf of MDI. On December 31, 2002, MDI recorded the full amount owing to the Clinic as a liability in its accounts. On October 22, 2003, MDI and the Clinic entered into a Revised Settlement Agreement and Mutual Release. MDI agreed to pay the sum of $240,000 to the Clinic which will be held in escrow pending the return of MDI's instruments and computer equipment used in the China Study and MDI's successful ability to access available and uncorrupted clinical trial data contained therein. If the China Study data is available, the Clinic agrees to provide all hard copy documentation related to the China Study and to complete a review and analysis of the data in a timely manner. If the data is not available, MDI's payments will be returned to MDI and the lawsuit will go forward. At that point MDI will actively defend itself based on the Clinic's failure to deliver the data required under the original China Study agreement. On January 2, 2003, Bowne of Chicago, Inc. ("Bowne") filed suit against MDI (Circuit Court of Cook County, Illinois (Case No. 03 L 000009)) claiming approximately $342,000, plus interest and costs, related to financial printing service fees provided to MDI by Bowne during the period October 25, 2001 through November 7, 2002. While MDI is actively defending itself against the suit claiming the charges for printing services provided during the period mentioned above were excessive, management has taken a conservative position and recorded the entire amount of the Bowne invoices as outstanding accounts payable on the records of MDI. As of December 31, 2002 and September 30, 2003, management and its counsel are unable to determine what the outcome of this litigation might be. 24 On January 9, 2003, Monsun, AS ("Monsun") filed suit against Peter Gombrich, MDI's Chairman and CEO, (United States District Court for the Northern District of Illinois Eastern Division (Case No. 03C 0184)) claiming damages in excess of $500,000 plus attorneys' fees and costs, and alleging breach of a Guaranty Agreement and a Letter Agreement signed by Mr. Gombrich in conjunction with Monsun's grant of an extension in the maturity date of a convertible promissory note in the principal amount of $500,000 issued by MDI on November 1, 2000. Monsun claims that Mr. Gombrich is obligated under the Guaranty Agreement to pay all monies owed by MDI under the convertible promissory note. MDI has recorded the principal amount of the note plus accrued and unpaid interest to December 31, 2002 as a note payable on its records. Regarding the Letter Agreement, Monsun claims that Mr. Gombrich was obligated to transfer to Monsun 200,000 registered shares of common stock of MDI held by Mr. Gombrich. Since Mr. Gombrich's potential liability in the suit, including delivery of 200,000 registered shares of MDI's common stock, is the result of the failure of MDI to pay the principal amount of its convertible promissory note when due, the Board of Directors has agreed that MDI will assume responsibility for Mr. Gombrich's obligations under the Guaranty Agreement and Letter Agreement, including legal costs. Regarding the claim for breach of the Guaranty Agreement, counsel for Mr. Gombrich has presented a settlement proposal. Monsun, counsel for Mr. Gombrich and the Company's counsel continue to discuss a settlement proposal, and management and counsel are unable to determine the result of this claim. With respect to the claim for breach of the Letter Agreement, on November 2003 Monsun and Mr. Gombrich reached a settlement agreement. In November 2002 and prior to the litigation, the Board of Directors approved the issuance of 200,000 shares of MDI's common stock to Monsun to satisfy Mr. Gombrich's alleged obligation under the Letter Agreement. The terms of the Letter Agreement stated that Monsun was to ultimately receive registered shares of MDI's common stock. However, MDI issued the shares of its common stock to Monsun with a restrictive legend which permits their sale only in compliance with Rule 144 of the Securities Act of 1933, as amended. Under the terms of the settlement agreement, Gombrich and/or MDI must either register the 200,000 shares previously transferred to Monsun or transfer 200,000 registered shares to Monsun on or before March 31, 2004. If Mr. Gombrich or MDI transfer additional shares, Monsun is required to return the previously transferred shares. MDI is a defendant in several lawsuits brought by current or former unsecured creditors to collect past due amounts for goods and services. MDI has recorded the amounts due in its records and is attempting to settle these suits and unfiled claims. MDI is a defendant in several legal actions brought by former employees seeking to collect amounts due for unpaid wages. MDI has recorded the amounts due in its records and is attempting to settle these actions and in some cases it is contesting such actions. In May 2003, the Company, together with its subsidiaries, AccuMed International, Inc. ("Accumed") and Oncometrics Imaging Corp. ("Oncometrics"), filed suit against MonoGen, Inc. ("MonoGen") and Norman J. Pressman, Docket No. 03 CH 08532 (Circuit Court of Cook County, Illinois). This suit arose out of two license agreements, one between AccuMed and MonoGen, and the other between Oncometrics and MonoGen, in which the rights to limited use of certain intellectual property were granted to MonoGen in return for one-time license fee payments totaling $500,000 (the "Agreements"). At the time that the Agreements were entered into, the Company had not yet acquired AccuMed and Oncometrics. A portion of the intellectual property subject to the Agreements had originally been licensed from the British Columbia Cancer Agency ("BCCA"). Pressman was the President of AccuMed and Oncometrics when the Agreements were negotiated and executed. Shortly after the Agreements were signed, Pressman became President of MonoGen. The Complaint filed in this case alleged that certain rights to the subject intellectual property were transferred to MonoGen at a below-market price. The Complaint also asserted that AccuMed and Oncometrics may not have obtained the requisite consent of BCCA to the Agreements. The Complaint also claims that, to the extent BCCA's consent was required, Pressman breached his fiduciary duties to AccuMed and Oncometrics by failing to obtain such consent, and also by negotiating below-market license fees with his future employer. The Company's claims against MonoGen were dismissed from this action. However, the Company's claims against Pressman remain pending. In June 2003, the Court dismissed the Company's request for an injunction against the defendants. This denial does not affect the Company's rights to pursue permanent injuntive relief at the conclusion of the case, if such is warranted. A Second Amended Verified Complaint was filed in this case on November 14, 2003. On November 20, 2003, AccuMed and Oncometrics sent termination notices to MonoGen with respect to the licenses previously granted by them to MonoGen. At the same time, the Company advised BCCA of its plan to settle directly with BCCA any differences it may have with BCCA in regard to the MonoGen licenses. The failure of the Company to negotiate a favorable settlement with BCCA in regard to any such differences could have adverse effect on certain limited aspects of the Company's business. On April 14, 2003, the Company received a notification from the attorney for Dr. Bruce Patterson, M.D., Ph.D, a licensor of the Company under the License and Development Agreement covering certain HPV technology, which forms the basis for our In-Cell HPV test, indicating that the licensor intended to terminate the license in accordance with a specific clause of the license, which permits termination in the event the Company makes an assignment for the benefit of creditors or bankruptcy, or otherwise relinquishes or loses control of all its assets. On April 15, 2003, we informed the attorney that the facts used by the licensor to invoke the termination right were incorrect and that we are still in control of all of our assets and that such assets are pledged as security under debt instruments and that such pledges are not included under events which would permit the licensor to terminate the license. We, and our counsel, believe that MDI would prevail should the licensor attempt to pursue a termination action. We are also engaged in a dispute with the licensor over completion of the third milestone of the license under which completion requires process and procedure verification by an independent third party. This verification requirement has not been satisfied as yet. On July 2, 2003, the licensor and his business, Inviron, Inc., filed suit against MDI (Circuit Court of Cook County, Illinois (Case No. 03 L007995)), claiming a total of $143,556.97 due under two separate contracts. The parties are in settlement discussions to resolve all outstanding issues. 25 Item 2. Changes in Securities and Use of Proceeds Beginning in October 2002, we began an issue of up to $4,000,000 in series Bridge II Convertible Promissory Notes to accredited investors. We issued $550,000 in Bridge II notes as of December 31, 2002. During the first nine months of 2003, we issued an additional $2,918,200 in principal amount of Bridge II notes. The notes bear interest at a rate of 12% per annum payable at the maturity date in kind in the form of shares of our common stock. We granted the holders a junior security position in all of our assets. The notes are convertible at any time into our common stock. The note conversion price and the value of common shares paid in kind as interest for the first $1,000,000 in principal amount of cash subscriptions, determined on a "first come - first served basis," is $0.10 per share. The note conversion price and the value of common shares paid in kind as interest for the remaining $3,000,000 of principal amount of notes in the series is $0.15 per share. The conversion price of the notes issued during 2002 and those issued during the first nine months of 2003 was less than the market price of the common stock when the notes were issued; therefore, the holder is considered to have a beneficial conversion feature. We determined the value of the beneficial conversion feature to be $2,051,200 and $330,000 at September 30, 2003 and December 31, 2002, respectively. The value was recorded as a reduction of the debt and will be amortized as additional interest over the life of the note. We recorded additional interest expense of $1,652,708 to reflect amortization of the discount for the nine months ended September 30, 2003. At the time we complete significant additional funding plans, as outlined in the subscription agreement, each holder of Bridge II notes is entitled to receive a warrant to purchase one share of our common stock for each four shares of common stock into which the note is convertible at an exercise price of $0.15 per share for notes in the class pertaining to the first $1,000,000 in subscriptions and $0.20 for the remaining $3,000,000 in note principal subscriptions. Subsequent to September 30, 2003, we issued additional notes in the Bridge II series. In September 2003 an amendment to the Bridge II Convertible Promissory Notes was sent to holders requesting an extension of the notes to July 31, 2004. As additional consideration for the extension, holders were offered an increase in the interest rate from 12% to 15%. In addition, an amendment to the indenture offered an increase in the warrant coverage ratio from 25% to 33%. (See Footnote 9: Subsequent Events) In June 2003, MDI issued 83,642 shares of restricted common stock in lieu of unpaid invoices for services owing to a non-employee vendor. MDI valued the shares at $12,463, which represented the amount of the unpaid invoices. In July 2003, MDI issued 1,375,000 shares of common stock to non-employees for past and future financing and consulting services. MDI calculated a fair value of $495,000 for these shares based on the fair market value of the shares on the date they were paid. Of the total amount $207,000 is being amortized over the life of the services contract. In August 2003, MDI issued 107,000 shares of common stock to a non-employee financial consultant for past financing services. MDI valued the shares at $51,000. The above issuances are deemed to be exempt under Rule 506 of Regulation D and Section 4(2) of the Securities Act of 1933, as amended. No advertising or general solicitation was employed in offering the securities. The offerings and sales or issuances were made to a limited number of persons, all of whom were accredited investors, business associates of the Company or executive officers of the Company, and transfer was restricted by the Company in accordance with the requirements of the Securities Act of 1933. In addition to representations by the above-referenced persons, the Company has made independent determinations that all of the investors were accredited or sophisticated investors, and that they were capable of analyzing the merits and risks of their investment, and that they understood the speculative nature of their investment. Furthermore, these investors were provided with access to our Securities and Exchange Commission filings. Item 3. Defaults upon Senior Securities MDI has failed to make the required principal and interest payments, constituting events of default, on the following notes payable: 26 o $2,125,000 in Bridge I convertible promissory notes; o $3,468,200 in Bridge II convertible promissory notes; o $618,000 Monsun AS convertible promissory note; o $211,368 Ungaretti & Harris secured promissory note; and o $40,000 Trek Diagnostics note payable The notes payable require the holder to notify MDI in writing of a declaration of default at which time a cure period, as specified in each individual note, would commence. There is no guarantee that MDI would be able to cure any event of default if, or when, the holder provides the required written notice. Other than the Monsun AS convertible promissory note and the Trek Diagnostics note payable, which are the subject of legal actions described under Part II Item 1 above and in Notes to Consolidated Financial Statements, Footnote 10 - Legal Proceedings, MDI has not received any written declarations of default from holders of outstanding notes payable. Item 4. Submission of Matters to a Vote of Security Holders None Item 5. Other Information None Item 6. Exhibits and Reports on Form 8-K (a) Exhibits Exhibit Number Description - ------- ----------- 4.40 Form of common stock purchase warrant issued to Dan Burns on August 20, 2003 representing the right to purchase 1,100,000 shares of common stock of the Company in connection with raising capital for the Company. 4.41 Form of common stock purchase warrant issued to Dan Burns on September 16, 2003 representing the right to purchase 935,000 shares of common stock of the Company in connection with raising capital for the Company. 4.42 Form of common stock purchase warrant issued to David Weissberg on September 16, 2003 representing the right to purchase 400,000 shares of common stock of the Company in connection with raising capital for the Company. 4.43 Form of common stock purchase warrant issued to Reid Jilek on September 2, 2003 representing the right to purchase 500,000 shares of common stock of the Company in connection with raising capital for the Company. 10.47 Amendment No.1 to the 12% Convertible Secured Promissory Note issued in connection with certain Bridge Financing in October 2002. 10.48 Amendment No. 1 to the Indenture issued in connection with certain Bridge Financing in October 2002 10.49 Form of consulting agreement with Dan Burns and Eugene Martineau for the purpose of assisting the Company in certain investor relations and other financial aspects of the Company. 10.50 Form of consulting agreement with Dr. Reid Jilek for the purpose of assisting the Company with Joint Ventures, licensing agreements, contracts, and equity and strategic funding sources. 31.1 Section 302 certification by principal executive officer. 27 31.2 Section 302 certification by principal financial officer. 32.1 Section 906 certification by principal executive officer. 32.2 Section 906 certification by principal financial officer. (b) Reports on Form 8-K None 28 Signatures In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Molecular Diagnostics, Inc. /s/ Peter P. Gombrich --------------------------------------- Peter P. Gombrich Chairman and Chief Executive Officer /s/ Dennis L. Bergquist --------------------------------------- Dennis L. Bergquist Chief Financial Officer Date: November 20, 2003 29 EXHIBIT INDEX 30 EX-31.1 3 v00796ex31-1_111803.txt Exhibit 31.1 CERTIFICATION I, Peter P. Gombrich, Chief Executive Officer certify that: 1. I have reviewed this Form 10-QSB/A of Molecular Diagnostics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report; 4. The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and 5. The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting. Date: November 20, 2003 /s/ Peter P. Gombrich - ------------------------------- Peter P. Gombrich Chief Executive Officer EX-31.2 4 v00796ex31-2_111803.txt Exhibit 31.2 CERTIFICATION I, Dennis Bergquist, Chief Financial Officer certify that: 1. I have reviewed this Form 10-QSB/A of Molecular Diagnostics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report; 4. The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and 5. The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting. Date: November 20, 2003 /s/ Dennis Bergquist - --------------------------- Dennis Bergquist Chief Financial Officer EX-32.1 5 v00796ex32-1_111803.txt Exhibit 32.1 Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002) I, Peter P. Gombrich, Chief Executive Officer (principal executive officer) of Molecular Diagnostics, Inc. (the "Registrant"), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-QSB/A for the period ended September 30, 2003 of the Registrant (the "Report"), that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2) The information contained in the Report fairly represents, in all material aspects, the financial condition and results of operations of the Registrant. Date: November 20, 2003 /s/ Peter P. Gombrich ----------------------------- Peter P. Gombrich NOTE: A signed original of this written statement required by Section 906 has been provided to Molecular Diagnostics, Inc. and will be retained by Molecular Diagnostics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by law, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. EX-32.2 6 v00796ex32-2_111803.txt Exhibit 32.2 Certification of Principal Financial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002) I, Dennis L. Bergquist, Chief Financial Officer (principal financial officer) of Molecular Diagnostics, Inc. (the "Registrant"), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-QSB/A for the period ended September 30, 2003 of the Registrant (the "Report"), that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2) The information contained in the Report fairly represents, in all material aspects, the financial condition and results of operations of the Registrant. Date: November 20, 2003 /s/ Dennis L. Bergquist ----------------------------- Dennis L. Bergquist NOTE: A signed original of this written statement required by Section 906 has been provided to Molecular Diagnostics, Inc. and will be retained by Molecular Diagnostics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by law, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. -----END PRIVACY-ENHANCED MESSAGE-----